Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jorge Pérez-Treviño"'
Autor:
Perla Pérez-Treviño, Héctor Hernández-De la Cerda, Jorge Pérez-Treviño, Oscar Raúl Fajardo-Ramírez, Noemí García, Julio Altamirano
Publikováno v:
Translational Oncology, Vol 11, Iss 3, Pp 672-685 (2018)
Patients with breast cancer (BC) overexpressing HER2 (HER2+) are selected for Trastuzumab treatment, which blocks HER2 and improves cancer prognosis. However, HER2+ diagnosis, by the gold standard, immunohistochemistry, could lead to errors, associat
Externí odkaz:
https://doaj.org/article/37c9ba06547d48f7afe141a07c96d79a
Autor:
Perla Pérez-Treviño, Jorge Pérez-Treviño, Cuauhtémoc Borja-Villa, Noemí García, Julio Altamirano
Publikováno v:
Cellular Physiology and Biochemistry, Vol 37, Iss 4, Pp 1329-1344 (2015)
Background/Aims: Pressure-overload (PO) causes cardiac hypertrophy (CH), and eventually leads to heart failure (HF). HF ventricular myocytes present transverse-tubules (TT) loss or disarrangement and decreased sarcoplasmic reticulum (SR) density, and
Externí odkaz:
https://doaj.org/article/b33cb446a03f43f1bea10e47473ccb44
Autor:
Jorge Pérez-Treviño, Héctor Hernández-De la Cerda, Julio Altamirano, Oscar R. Fajardo-Ramírez, Perla Pérez-Treviño, Noemí García
Publikováno v:
Translational Oncology, Vol 11, Iss 3, Pp 672-685 (2018)
Translational Oncology
Translational Oncology
Patients with breast cancer (BC) overexpressing HER2 (HER2+) are selected for Trastuzumab treatment, which blocks HER2 and improves cancer prognosis. However, HER2+ diagnosis, by the gold standard, immunohistochemistry, could lead to errors, associat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c84915e40562591766131051a1d16614
http://www.sciencedirect.com/science/article/pii/S1936523318300068
http://www.sciencedirect.com/science/article/pii/S1936523318300068